Skip to main content
SpringerLink
Log in

Überlegenheit des neuen Wirkstoffs LCZ696 gegenüber Enalapril bei der Behandlung der systolischen Herzinsuffizienz

PARADIGM-HF-Studie

Superiority of the new agent LCZ696 for treatment of systolic heart failure compared to enalapril

PARADIGM-HF study

  • Journal Club
  • Published:
Der Kardiologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004

    CAS  PubMed  Google Scholar 

  2. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302

    Article  Google Scholar 

  3. Cohn JN, Tognoni G, Valsartan Heart Failure Trial I (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–1675

    Article  CAS  PubMed  Google Scholar 

  4. Jessup M (2014) Neprilysin inhibition – a novel therapy for heart failure. N Engl J Med 371:1062–1064

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

C. Özcelik gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Medizinische Klinik I, Klinikum Vest GmbH, Behandlungszentrum, Knappschaftskrankenhaus Recklinghausen, Dorstener Str. 151, 45657, Recklinghausen, Deutschland

    C. Özcelik

Authors
  1. C. Özcelik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Özcelik.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Özcelik, C. Überlegenheit des neuen Wirkstoffs LCZ696 gegenüber Enalapril bei der Behandlung der systolischen Herzinsuffizienz. Kardiologe 8, 443–445 (2014). https://doi.org/10.1007/s12181-014-0627-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-014-0627-3

Search

Navigation